Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial
Stefan D Anker,Javed Butler,Gerasimos S Filippatos,Waheed Jamal,Afshin Salsali,Janet Schnee,Karen Kimura,Cordula Zeller,Jyothis George,Martina Brueckmann,Faiez Zannad,Milton Packer,EMPEROR-Preserved Trial Committees and Investigators,Sergio Perrone,Stephen Nicholls,Stefan Janssens,Edmar Bocchi,Nadia Giannetti,Subodh Verma,Zhang Jian,Juan Esteban Gomez Mesa,Jindrich Spinar,Michael Böhm,Bela Merkely,Vijay Chopra,Michele Senni,Stefano Taddi,Hiroyuki Tsutsui,Eduardo Chuquiure,Hans Pieter Brunner La Rocca,Piotr Ponikowski,Dragos Vinereanu,David Sim,Dong-Ju Choi,Jose Ramon Gonzalez Juanatey,Iain Squire,James Januzzi,Ileana Pina,Stuart J Pocock,Peter Carson,Wolfram Doehner,Alan Miller,Markus Haas,Steen Pehrson,Michel Komajda,Inder Anand,John Teerlink,Alejandro Rabinstein,Thorsten Steiner,Hooman Kamel,Georgios Tsivgoulis,James Lewis,James Freston,Neil Kaplowitz,Johannes Mann,Mark Petrie,Richard Bernstein,Alfred Cheung,Jennifer Green,Sanjay Kaul,Carolyn Lam Su Ping,Gregory Lip,Nikolaus Marx,Peter McCullough,Cyrus Mehta,Julio Rosenstock,Naveed Sattar,Benjamin Scirica,Christoph Wanner,Francine K Welty,Klaus G Parhofer,Tim Clayton,Terje R Pedersen,Kennedy R Lees,Marvin A Konstam,Barry Greenberg,Mike Palmer
DOI: https://doi.org/10.1002/ejhf.1596
Abstract:Background: The principal biological processes that characterize heart failure with a preserved ejection fraction (HFpEF) are systemic inflammation, epicardial adipose tissue accumulation, coronary microcirculatory rarefaction, myocardial fibrosis and vascular stiffness; the resulting impairment of left ventricular and aortic distensibility (especially when accompanied by impaired glomerular function and sodium retention) causes increases in cardiac filling pressures and exertional dyspnoea despite the relative preservation of left ventricular ejection fraction. Independently of their actions on blood glucose, sodium-glucose co-transporter 2 (SGLT2) inhibitors exert a broad range of biological effects (including actions to inhibit cardiac inflammation and fibrosis, antagonize sodium retention and improve glomerular function) that can ameliorate the pathophysiological derangements in HFpEF. Such SGLT2 inhibitors exert favourable effects in experimental models of HFpEF and have been found in large-scale trials to reduce the risk for serious heart failure events in patients with type 2 diabetes, many of whom were retrospectively identified as having HFpEF. Study design: The EMPEROR-Preserved Trial is enrolling ≈5750 patients with HFpEF (ejection fraction >40%), with and without type 2 diabetes, who are randomized to receive placebo or empagliflozin 10 mg/day, which is added to all appropriate treatments for HFpEF and co-morbidities. Study aims: The primary endpoint is the time-to-first-event analysis of the combined risk for cardiovascular death or hospitalization for heart failure. The trial will also evaluate the effects of empagliflozin on renal function, cardiovascular death, all-cause mortality and recurrent hospitalization events, and will assess a wide range of biomarkers that reflect important pathophysiological mechanisms that may drive the evolution of HFpEF. The EMPEROR-Preserved Trial is well positioned to determine if empagliflozin can have a meaningful impact on the course of HFpEF, a disorder for which there are currently few therapeutic options.